Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tirzepatide in Women With Obesity and EIN or Grade 1 Endometrial Cancer
NCT07078838Phase 2Not yet recruiting
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Start
- Jan 2027
- Primary completion
- Mar 2029
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tirzepatide in Endometrial intraepithelial neoplasia (EIN) and endometrial cancer (EC) (2 arms), sponsored by UNC Lineberger Comprehensive Cancer Center. Primary endpoint: Anti-proliferative effect of Tirzepatide at 4 weeks. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
03
Conditions
Endometrial intraepithelial neoplasia (EIN)endometrial cancer (EC)
Beyond the preview
Go deeper on NCT07078838.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07078838.